William Blair analyst Myles Minter has reiterated their bullish stance on ARCT stock, giving a Buy rating on October 10.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Myles Minter has given his Buy rating due to a combination of factors surrounding Arcturus Therapeutics’ ongoing developments. Despite the interim Phase II data for ARCT-032 missing the expected improvement in lung function (ppFEV1) in cystic fibrosis patients, the therapy shows potential in other areas. The inhaled mRNA therapy demonstrated a tolerable safety profile, which is promising given the daily inhalation requirement over a 28-day period.
Furthermore, Arcturus is planning a 12-week efficacy study in 2026, which could provide more insights into the therapy’s potential benefits. The possibility of longer treatment duration or higher dosing could enhance efficacy signals, particularly in mucus clearance, which might eventually lead to improvements in lung function. These factors contribute to the optimism surrounding Arcturus’ future prospects, justifying the Buy rating.
In another report released on October 10, Citi also maintained a Buy rating on the stock with a $49.00 price target.